In a pooled analysis of the phase III BROADWAY and BROOKLYN trials, treatment with the cholesteryl ester transfer protein inhibitor obicetrapib significantly reduced major adverse cardiovascular events in adults with atherosclerotic cardiovascular disease or familial hypercholesterolemia on maximally tolerated lipid-lowering therapy. Over 12 months, obicetrapib lowered low-density lipoprotein cholesterol by 37.8%, apolipoprotein B by 21.7%, non–high-density lipoprotein cholesterol by 32.4%, and lipoprotein(a) by 32.5%, while raising high-density lipoprotein cholesterol by 140% versus placebo. Cardiovascular benefits emerged after 6 months, suggesting obicetrapib provides meaningful event reduction through broad atherogenic lipid lowering in high-risk patients. 

Source: JACC